Physician profile
Matthew Chase
NPI 1215339486
$520.81
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $48.62 · 2021: $79.95 · 2022: $73.43 · 2023: $19.63 · 2024: $73.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $111.58 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $71.88 | 2019-2021 | |
| Abbvie INC. | $49.57 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $47.68 | 2019 | |
| Abbott Laboratories | $36.32 | 2022-2024 | Freestyle Libre 3 |
| Shire North American Group INC | $30.70 | 2019 | |
| Scilex Pharmaceuticals INC. | $28.12 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.26 | 2020 | |
| Nevro Corp. | $18.05 | 2021 | |
| Vivus LLC | $15.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.12 | 2019 | |
| Genentech USA, INC. | $12.80 | 2020 | |
| Cranial Technologies, INC | $12.51 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.34 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $11.67 | 2021 | |
| Bausch Health US, LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.